Vanguard Portfolio Management
DMAC icon

Vanguard Portfolio Management’s DiaMedica Therapeutics DMAC Stock Holding History

Vanguard Portfolio Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.12M Buy
256,510
+4,839
+2% +$33.8K ﹤0.01% 2681
2026
Q2 		$1.77M Buy
251,671
+48,212
+24% +$296K ﹤0.01% 2785
2026
Q1 		$1.38M Buy
+203,459
New +$1.61M ﹤0.01% 2700

Other funds holding DMAC

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Bleichroeder LP
Bleichroeder LP New York $1.02B AUM 33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Cobalt Capital Management
Cobalt Capital Management Short Hills, New Jersey $174M AUM 39.41% 1-Year Est. Return

Vanguard Portfolio Management's DMAC Position: Q3 2026 in Review

Vanguard Portfolio Management increased its DiaMedica Therapeutics (DMAC) stake by 1.9% in Q3 2026, buying an estimated $33.8K and bringing the position to 256,510 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2681.

Vanguard Portfolio Management first reported a position in DMAC in Q1 2026 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

  • Vanguard Portfolio Management held 256,510 shares of DiaMedica Therapeutics worth $2.12M as of Q3 2026.
  • Vanguard Portfolio Management bought 4,839 DiaMedica Therapeutics shares in Q3 2026, an estimated $33.8K.
  • DiaMedica Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #2681 holding.
  • Vanguard Portfolio Management first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.